Crinetics Pharmaceuticals, Inc. (CRNX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:27AM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 4.01B |
| Enterprise value | 3.50B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 736.41 |
| Price/book (mrq) | 7.43 |
| Enterprise value/revenue | 872.28 |
| Enterprise value/EBITDA | -15.80 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.63 |
| 52-week change 3 | 130.17% |
| S&P500 52-week change 3 | 25.59% |
| 52-week high 3 | 51.29 |
| 52-week low 3 | 15.76 |
| 50-day moving average 3 | 44.21 |
| 200-day moving average 3 | 32.99 |
Share statistics
| Avg vol (3-month) 3 | 829.05k |
| Avg vol (10-day) 3 | 795.96k |
| Shares outstanding 5 | 78.74M |
| Implied shares outstanding 6 | 78.74M |
| Float 8 | 64.8M |
| % held by insiders 1 | 2.12% |
| % held by institutions 1 | 97.47% |
| Shares short (15 Apr 2024) 4 | 5.22M |
| Short ratio (15 Apr 2024) 4 | 4.77 |
| Short % of float (15 Apr 2024) 4 | 6.78% |
| Short % of shares outstanding (15 Apr 2024) 4 | 6.63% |
| Shares short (prior month 15 Mar 2024) 4 | 5.01M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -5,547.17% |
Management effectiveness
| Return on assets (ttm) | -28.18% |
| Return on equity (ttm) | -50.16% |
Income statement
| Revenue (ttm) | 4.01M |
| Revenue per share (ttm) | 0.07 |
| Quarterly revenue growth (yoy) | -100.00% |
| Gross profit (ttm) | N/A |
| EBITDA | -221.51M |
| Net income avi to common (ttm) | -214.53M |
| Diluted EPS (ttm) | -3.69 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 558.56M |
| Total cash per share (mrq) | 8.03 |
| Total debt (mrq) | 51.73M |
| Total debt/equity (mrq) | 9.59% |
| Current ratio (mrq) | 13.07 |
| Book value per share (mrq) | 7.91 |
Cash flow statement
| Operating cash flow (ttm) | -166.31M |
| Levered free cash flow (ttm) | -93.53M |
© 2024 Yahoo. All rights reserved.